# Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

> **NCT01731951** · PHASE2 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 80 (actual)

## Conditions studied

- Primary Myelofibrosis
- Secondary Myelofibrosis
- Myeloid Malignancies

## Interventions

- **DRUG:** Imetelstat

## Key facts

- **NCT ID:** NCT01731951
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-29
- **Primary completion:** 2018-05-24
- **Final completion:** 2018-05-24
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01731951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01731951, "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT01731951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*